Table 3 Factors associated with treatment non-completion.

Variable	Univariable analysis		Multivariable analysis
Variable	OR (95% CI)	P value	OR^a (95% CI)	P value
TBI regimen
9H	Reference	–
1HP	1.51 (0.41–5.60)	0.540
3HP	2.12 (0.84–5.36)	0.114
Age, per 1-year increase	1.06 (1.02–1.10)	0.001	1.07 (1.02–1.11)	0.002
Male sex	0.19 (0.07–0.54)	0.002	0.27 (0.09–0.85)	0.025
Risk group for HIV transmission
Men who have sex with men	Reference	–
Heterosexuals	1.51 (0.41–5.60)	0.540
Illicit drug users	2.12 (0.84–5.36)	0.114
Body-mass index, per 1-kg/m² increase	1.09 (0.95–1.26)	0.218
History of incarceration	0.47 (0.06–3.66)	0.473
HBsAg positivity	1.90 (0.52–6.93)	0.330
Anti-HCV positivity	5.07 (2.11–12.21)	< 0.001	4.45 (1.73–11.47)	0.002
Cardiovascular disease	0.47 (0.06–3.66)	0.473
Diabetes mellitus	0.80 (0.10–6.38)	0.836
ART during TBI treatment
Bictegravir-containing regimen	1.47 (0.16–13.54)	0.736
Dolutegravir-containing regimen	5.07 (0.66–39.90)	0.119
Others	Reference	–
CD4 count before TBI treatment, per 10-cells/mm³ increase	0.99 (0.98–1.01)	0.200
PVL before TBI treatment, per 1-log₁₀ copies/mL increase	1.90 (1.19–3.03)	0.007	1.78 (1.07–2.95)	0.026

1HP One month of daily rifapentine plus isoniazid, 3HP Three months of weekly rifapentine plus isoniazid, ART Combination antiretroviral therapy, HBsAg Hepatitis B surface antigen, HCV Hepatitis C virus, TBI Tuberculosis infection, OR Odds ratio, PVL Plasma HIV RNA load.
^aFor the estimates of the effect of covariates on treatment noncompletion, the ORs are adjusted for age, sex, anti-HCV positivity, and PVL before TBI treatment using logistic regression analysis.

Quick links

Search